X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HEMO-CAR-T cell therapy is developed using Hemogenyx’s proprietary humanised monoclonal antibody. It is being evaluated in preclinical studies for the treatment of acute myeloid leukemia.
Lead Product(s): HEMO-CAR-T
Therapeutic Area: Oncology Product Name: HEMO-CAR-T
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
Human macrophages, a type of immune cells, programmed with a purpose designed CBR, were able to eliminate Non-Hodgkin Lymphoma derived cells with high efficiency in vitro.
Lead Product(s): Human Macrophage-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Under the terms of the MSTA, InfoWorks is to provide clinical services and technologies for the Company's upcoming Phase I study of its anti-FLT3 chimeric antigen receptor-redirected T cells (CAR-T cells) in subjects with relapsed/refractory acute myeloid leukemia (AML).
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Prevail InfoWorks
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 18, 2023
Details:
HEMO-CAR-T is made using Hemogenyx’s proprietary humanised monoclonal antibody against a target on the surface of AML cells and potential treatment of Acute Myeloid Leukemia.
Lead Product(s): HEMO-CAR-T
Therapeutic Area: Oncology Product Name: HEMO-CAR-T
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
HEMO-CAR-T is being clinically evaluated for treating acute myeloid leukemia (AML). CAR-T therapy is a treatment in which a patient’s own T-cells, a type of immune cell, are modified to recognize and kill the patient’s cancer cells.
Lead Product(s): HEMO-CAR-T
Therapeutic Area: Oncology Product Name: HEMO-CAR-T
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
Under the agreement, Hemogenyx will leverage Selexis’ proprietary SUREtechnology Platform™, a suite of cell line development tools and technologies that significantly reduces the time, effort, and costs associated with developing high-performance mammalian cell lines.
Lead Product(s): CDX bi-specific antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: KBI Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 12, 2022
Details:
Under this Agreement, Lilly grants the Company an exclusive worldwide licence to certain intellectual property developed by Lilly related to a CDX bispecific antibody for all uses, including the treatment of acute myeloid leukemia and other blood cancers.
Lead Product(s): CDX bi-specific Antibody
Therapeutic Area: Oncology Product Name: CDX bi-specific Antibody
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Eli Lilly
Deal Size: $1.2 million Upfront Cash: $0.2 million
Deal Type: Licensing Agreement October 13, 2021
Details:
Agreement focused on advancing Chimeric Antigen Receptor T-cells ("HEMO-CAR-T") developed by Hemogenyx toward clinical trials and is envisaged as the first step of a larger program aimed at achieving clinical proof of concept for HEMO-CAR-T to treat AML.
Lead Product(s): CAR-T therapy
Therapeutic Area: Oncology Product Name: HEMO-CAR-T
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: University of Pennsylvania
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 11, 2020
Details:
GlobalCo will supply the Company with certain biological materials and related confidential information in order for the Company to perform research and development activities to discover and validate novel materials for the treatment of SLE and ther autoimmune diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Hemogenyx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
